Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Brace Pharma Capital is a strategic investment firm established by EMS S/A, the largest pharmaceutical company in Brazil, alongside high net worth biotech investors. The firm is dedicated to investing in innovative therapies that address diseases with a high degree of unmet medical need and insufficient treatment options. Founded with the goal of transforming the healthcare landscape, Brace Pharma Capital has positioned itself as a key player in the biotechnology and pharmaceutical sectors.
Currently, the firm manages a portfolio of 10 notable companies, focusing on global investments that span various therapeutic areas. The firm operates from its office located in Atlanta, Georgia, and has built a reputation for its commitment to supporting life-changing treatments. Brace Pharma Capital's unique combination of resources and expertise allows it to effectively identify and nurture promising biotech innovations.
Brace Pharma Capital invests primarily in innovative therapies that target diseases with significant unmet medical needs. The firm emphasizes life-changing treatments within the biotechnology and pharmaceutical sectors, seeking to address health conditions that lack sufficient treatment options. Their investment strategy includes a focus on companies developing novel therapeutics for cancer, genetic disorders, and infectious diseases.
The firm typically engages in early to growth-stage investments, providing capital that supports the development of groundbreaking therapies. Brace Pharma Capital is particularly interested in companies that demonstrate a clear potential for impact in the healthcare market, and they prefer to collaborate with founders who share a vision for addressing critical health challenges.
Brace Pharma Capital's portfolio includes 10 notable companies, each engaged in developing innovative therapies:
This diverse portfolio reflects Brace Pharma Capital's commitment to supporting innovative solutions in the biotech and healthcare sectors.
Daniel E. Salazar, Ph.D.: Vice President of Clinical & Regulatory. Dr. Salazar has extensive experience in clinical development and regulatory affairs, having worked with various biotech firms prior to joining Brace Pharma Capital.
Todd Brady: Director of Finance & Investments. Brady has a strong background in finance and investment management, with a focus on the biotech sector, and has led several successful funding rounds for emerging companies.
Startups interested in pitching to Brace Pharma Capital should send their proposals via email to info@bracepharma.com. A detailed pitch deck should include information about the team, the therapeutic area, and the market potential. Founders can expect a response within a few weeks, depending on the volume of inquiries.
As of October 2023, Brace Pharma Capital continues to expand its portfolio, focusing on innovative therapies in the biotech sector. The firm has recently made investments in several promising companies, although specific details on these transactions have not been disclosed.
Brace Pharma Capital remains active in the investment community, leveraging its connections and expertise to identify and support startups that align with its mission of addressing unmet medical needs.
What are Brace Pharma Capital's investment criteria?
Brace Pharma Capital focuses on innovative therapies that address significant unmet medical needs, particularly in the biotechnology and pharmaceutical sectors. They seek companies developing life-changing treatments.
How can startups apply or pitch to Brace Pharma Capital?
Startups can reach out via email at info@bracepharma.com to initiate discussions about potential investment opportunities. A well-prepared pitch deck detailing the company's vision and therapeutic focus is recommended.
What makes Brace Pharma Capital different from other investors?
The firm is uniquely positioned due to its affiliation with EMS S/A, Brazil's largest pharmaceutical company, which provides extensive industry insights and resources. Their focus on unmet medical needs sets them apart in the investment landscape.
What is the geographic scope of Brace Pharma Capital's investments?
Brace Pharma Capital invests globally, targeting innovative biotech and healthcare companies regardless of their location, as long as they align with the firm's investment thesis.
What is the typical check size for investments?
While specific check sizes are not disclosed, Brace Pharma Capital typically invests in early to growth-stage companies, providing substantial capital to support their development.
What level of post-investment involvement can startups expect?
Brace Pharma Capital actively engages with portfolio companies, offering mentorship and access to their network, which can be crucial for navigating the biotech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.